CN104363898A - [(1s)-1-{[(2s,4r)-4-(7-氯-4-甲氧基异喹啉-1-基氧基)-2-({(1r,2s)-1-[(环丙基磺酰基)氨甲酰基]-2-乙烯基环丙基}氨甲酰基)吡咯烷-1-基]羰基}-2,2-二甲基丙基]氨基甲酸1,1-二甲基乙基酯的口服固体给药制剂 - Google Patents

[(1s)-1-{[(2s,4r)-4-(7-氯-4-甲氧基异喹啉-1-基氧基)-2-({(1r,2s)-1-[(环丙基磺酰基)氨甲酰基]-2-乙烯基环丙基}氨甲酰基)吡咯烷-1-基]羰基}-2,2-二甲基丙基]氨基甲酸1,1-二甲基乙基酯的口服固体给药制剂 Download PDF

Info

Publication number
CN104363898A
CN104363898A CN201380023730.7A CN201380023730A CN104363898A CN 104363898 A CN104363898 A CN 104363898A CN 201380023730 A CN201380023730 A CN 201380023730A CN 104363898 A CN104363898 A CN 104363898A
Authority
CN
China
Prior art keywords
formulation
weight
compound
range
present application
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380023730.7A
Other languages
English (en)
Chinese (zh)
Inventor
R·哈米
P·潘迪
D·S·宾德拉
C·维玛瓦拉普
R·K·佩龙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN104363898A publication Critical patent/CN104363898A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201380023730.7A 2012-05-07 2013-05-03 [(1s)-1-{[(2s,4r)-4-(7-氯-4-甲氧基异喹啉-1-基氧基)-2-({(1r,2s)-1-[(环丙基磺酰基)氨甲酰基]-2-乙烯基环丙基}氨甲酰基)吡咯烷-1-基]羰基}-2,2-二甲基丙基]氨基甲酸1,1-二甲基乙基酯的口服固体给药制剂 Pending CN104363898A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261643486P 2012-05-07 2012-05-07
US61/643,486 2012-05-07
PCT/US2013/039378 WO2013169577A1 (en) 2012-05-07 2013-05-03 Oral solid dosage formulation of 1,1-dimethylethyl [(1s)-1-{[(2s,4r)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-({(1r,2s)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate

Publications (1)

Publication Number Publication Date
CN104363898A true CN104363898A (zh) 2015-02-18

Family

ID=48428704

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380023730.7A Pending CN104363898A (zh) 2012-05-07 2013-05-03 [(1s)-1-{[(2s,4r)-4-(7-氯-4-甲氧基异喹啉-1-基氧基)-2-({(1r,2s)-1-[(环丙基磺酰基)氨甲酰基]-2-乙烯基环丙基}氨甲酰基)吡咯烷-1-基]羰基}-2,2-二甲基丙基]氨基甲酸1,1-二甲基乙基酯的口服固体给药制剂

Country Status (6)

Country Link
US (1) US20150119317A1 (enExample)
EP (1) EP2846778B1 (enExample)
JP (1) JP2015516421A (enExample)
CN (1) CN104363898A (enExample)
ES (1) ES2673870T3 (enExample)
WO (1) WO2013169577A1 (enExample)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1863518A (zh) * 2003-10-03 2006-11-15 爱的发制药集团 含有非诺贝特的药物组合物及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US20050249702A1 (en) * 2004-05-06 2005-11-10 Schering Corporation (1R,2S,5S)-N-[(1S)-3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2S)-2-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide as inhibitor of hepatitis C virus NS3/NS4a serine protease
HRP20140097T1 (hr) * 2008-11-21 2014-03-14 Boehringer Ingelheim International Gmbh Farmaceutski sastav jakog hcv-inhibitora za oralnu primjenu
NZ605440A (en) * 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
US20130172239A1 (en) * 2011-12-29 2013-07-04 Abbvie Inc. Solid compositions
US20130302414A1 (en) * 2012-05-07 2013-11-14 Bristol-Myers Squibb Company Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1-carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1863518A (zh) * 2003-10-03 2006-11-15 爱的发制药集团 含有非诺贝特的药物组合物及其制备方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FEIYAN JIN ETAL: "Tabletability assessment of conventional formulations containing Vitamin E tocopheryl polyethylene glycol succinate", 《INTERNATIONAL JOURNAL OF PHARMACEUTICS》, vol. 389, 18 January 2010 (2010-01-18), pages 58 - 65, XP028308321, DOI: 10.1016/j.ijpharm.2010.01.017 *
KAZUAKI CHAYAMA ETAL: "Dual Therapy With the Nonstructural Protein 5A Inhibitor, Daclatasvir, and the Nonstructural Protein 3 Protease Inhibitor, Asunaprevir, in Hepatitis C Virus Genotype 1b-Infected Null Responders", 《HEPATOLOGY》, vol. 55, no. 3, 31 March 2012 (2012-03-31), pages 742 - 748, XP055071008, DOI: 10.1002/hep.24724 *

Also Published As

Publication number Publication date
US20150119317A1 (en) 2015-04-30
EP2846778A1 (en) 2015-03-18
EP2846778B1 (en) 2018-04-25
WO2013169577A1 (en) 2013-11-14
ES2673870T3 (es) 2018-06-26
JP2015516421A (ja) 2015-06-11

Similar Documents

Publication Publication Date Title
CN102946869B (zh) γ-羟基丁酸的速释制剂及剂型
CN101594851B (zh) 用于口服给药的酪氨酸激酶抑制剂的药物剂型
KR101925671B1 (ko) 데페라시록스의 경구 제제
CA2720658C (en) Improved formulations for poorly permeable active pharmaceutical ingredients
JP6216325B2 (ja) 医薬製剤
US9763885B2 (en) Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases
CN101969931A (zh) 包含霉酚酸的调节释放药物组合物及其方法
JP2010509289A (ja) チロシンキナーゼ阻害剤の経口投与用薬学的剤形
JP2015120700A (ja) ステロイド組成物
JP2007517879A (ja) Ｃｃｉ−７７９経口投与用の直接圧縮可能な医薬組成物
CN101119709A (zh) 口服生物有效的cci-779配方
WO2013166114A1 (en) Oral tablet formulation consisting of fixed combination of atorvastatin and ezetimibe
WO2018108157A1 (zh) 一种瑞卡帕布口服缓控释药物组合物及其用途
WO2008104852A2 (en) Pharmaceutical compositions comprising adsorbate of fenofibrate
JP2018516942A (ja) 生体利用率が改善された含プランルカスト固形製剤の組成物及びその製造方法
CN118284415B (zh) 一种达罗他胺药物组合物及其制备方法和用途
US10376470B2 (en) Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases
CN104363898A (zh) [(1s)-1-{[(2s,4r)-4-(7-氯-4-甲氧基异喹啉-1-基氧基)-2-({(1r,2s)-1-[(环丙基磺酰基)氨甲酰基]-2-乙烯基环丙基}氨甲酰基)吡咯烷-1-基]羰基}-2,2-二甲基丙基]氨基甲酸1,1-二甲基乙基酯的口服固体给药制剂
WO2010010367A1 (en) Solid pharmaceutical composition comprising exemestane
JP2016539141A (ja) 医薬組成物
WO2012097222A1 (en) High drug load tablet formulation of brivanib alaninate
KR20200014076A (ko) 용출률 및 경구 흡수율이 개선된 셀레콕시브 고체 분산체 및 이의 제조방법
WO2025163665A1 (en) Stable pharmaceutical compositions of abiraterone
JP2009501796A (ja) 睡眠薬の放出調整
CN118948788A (zh) 一种吲哚布芬口服固体制剂及其制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20150218